Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis
Metrics: PDF 1881 views | HTML 2111 views | ?
Shengkang Dai1, Yan Lu1, Ying Long1, Yuehua Lai1, Ping Du1, Nan Ding1, Desheng Yao1
1Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
Desheng Yao, e-mail: [email protected]
Keywords: microRNA, prognosis, cervical carcinoma, meta-analysis
Received: December 08, 2015 Accepted: April 11, 2016 Published: May 11, 2016
This systematic review is written to investigate the outcome of cervical cancer. A comprehensive search of PubMed and EMBASE was performed to identify eligible studies. Nineteen studies from thirteen articles with a total of 1,310 participants were included in this meta-analysis. Overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) as a prognosis for cervical cancer were extracted and calculated, if available. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using STATA (version 12.0), resulting in the pooled HRs 0.70 (95% CI: 0.51–0.97) for OS, 1.02 (95% CI: 0.53–1.98) for DFS, and 0.56 (95% CI: 0.40–0.77) for RFS. The results indicated that cervical cancer patients with decreased microRNA expression were associated with shorter OS and RFS. It suggested that microRNAs might be promising markers for predicting the survival rate of cervical cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.